Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients
Status:
Recruiting
Trial end date:
2021-10-30
Target enrollment:
Participant gender:
Summary
This is a Phase IIa (proof of concept), randomized, double blind, placebo-controlled,
multicentre clinical trial to evaluate the safety and efficacy of daily PBF-677 oral
treatment during 28 days in Ulcerative colitis (UC) patients who are not receiving
immunosuppressants and present mild-to-moderate activity of the disease. Enrolled patients
would receive standard high doses of 5-ASA (4g), according to current clinical guidelines,
and are randomized to receive also PBF-677 or placebo.